查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1556750

蜂群刺激因子市场报告：2030 年趋势、预测与竞争分析

Colony Stimulating Factor Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

集落刺激因子的趋势和预测

到 2030 年，全球菌落刺激因子市场预计将达到 137 亿美元，2024 年至 2030 年复合年增长率为 10.4%。该市场的主要驱动因素是癌症和血液疾病盛行率的增加、创新疗法研发投资的增加以及对先进癌症治疗的需求不断增长。全球集落刺激因子市场的未来充满希望，医院、专科诊所和居家医疗市场都有机会。

按细分市场分類的集落刺激因子

本研究包括按类型、施用方法、应用、最终用途和区域对全球集落刺激因子进行预测。

集落刺激因子市场洞察

Lucintel 预测，注射剂将在预测期内达到最高成长。

在这个市场中，由于越来越多地采用居家医疗作为降低医疗保健成本和改善患者治疗效果的一种方式，居家医疗预计将显示出最高的增长。

由于人口癌症发病率不断上升以及该地区拥有强大的医疗保健系统，预计北美在预测期内仍将是最大的地区。

常问问题

Q1.市场规模为：

A1. 到 2030 年，全球菌落刺激因子市场预计将达到 137 亿美元。

Q2.市场成长预测是多少：

A2. 2024 年至 2030 年，全球集落刺激因子市场预计将以 10.4% 的复合年增长率成长。

Q3.影响市场成长的主要驱动因素是：

A3. 该市场的主要驱动力是癌症和血液疾病盛行率的增加、创新疗法研发投资的增加以及对先进癌症治疗的需求不断增长。

Q4.市场的主要细分市场是：

A4. 集落刺激因子市场前景广阔，在医院、专科诊所和居家医疗市场都有机会。

Q5.市场的主要企业是：

A5. 主要的集落刺激因子公司如下：

  • Intas Pharmaceuticals
  • Sanofi
  • Novartis
  • Teva Pharmaceutical Industries
  • Pfizer
  • GlaxoSmithKline
  • Biocon
  • Dr. Reddy's Laboratories
  • Amgen
  • Merck

Q6.未来最大的细分市场是什么？

A6.Lucintel预测，注射剂将在预测期内出现最高成长。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 由于人口癌症发生率不断上升以及该地区拥有强大的医疗保健系统，北美在预测期内仍将是最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章 全球集落刺激因子市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球菌落刺激因子市场趋势（2018-2023）与预测（2024-2030）
  • 全球集落刺激因子市场（按类型）
    • 巨噬细胞集落刺激因子
    • 多种集落刺激因子或白细胞介素3
    • 粒细胞-巨噬细胞集落刺激因子
    • 颗粒细胞增生因子
  • 按管理方法分類的全球集落刺激因子市场
    • 注射
    • 药片
    • 胶囊
    • 其他的
  • 按应用分類的集落刺激因子的全球市场
    • 再生障碍性贫血
    • 骨髓移植
    • 嗜中性白血球低下症
    • 化疗相关的嗜中性白血球低下症
    • 放射线相关的嗜中性白血球低下症
    • 週边血干细胞移植
  • 以最终用途分類的全球集落刺激因子市场
    • 医院
    • 专科诊所
    • 居家医疗
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球集落刺激因子市场（按地区）
  • 北美集落刺激因子市场
  • 欧洲集落刺激因子市场
  • 亚太集落刺激因子市场
  • 其他地区集落刺激因子市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球集落刺激因子市场类型的成长机会
    • 按管理方法分類的全球菌落刺激因子市场成长机会
    • 全球菌落刺激因子市场成长机会（按应用）
    • 全球菌落刺激因素市场成长机会（依最终用途）
    • 全球菌落刺激因素市场成长机会（按地区）
  • 全球集落刺激因子市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 全球集落刺激因子市场产能扩张
    • 全球集落刺激因子市场的合併、收购与合资企业
    • 认证和许可

第七章主要企业概况

  • Intas Pharmaceuticals
  • Sanofi
  • Novartis
  • Teva Pharmaceutical Industries
  • Pfizer
  • GlaxoSmithKline
  • Biocon
  • Dr. Reddy's Laboratories
  • Amgen
  • Merck
简介目录

Colony Stimulating Factor Trends and Forecast

The future of the global colony stimulating factor market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global colony stimulating factor market is expected to reach an estimated $13.7 billion by 2030 with a CAGR of 10.4% from 2024 to 2030. The major drivers for this market are increasing prevalence of cancer and hematological diseases, rising investments in research and development for innovative treatments, and growing demand for advanced cancer therapies.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Colony Stimulating Factor by Segment

The study includes a forecast for the global colony stimulating factor by type, dosage, application, end use, and region.

Colony Stimulating Factor Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Macrophage-Colony-Stimulating Factor
  • Multiple-Colony-Stimulating Factor or Interleukin 3
  • Granulocyte-Macrophage-Colony-Stimulating Factor
  • Granulocyte-Colony-Stimulating Factor

Colony Stimulating Factor Market by Dosage [Shipment Analysis by Value from 2018 to 2030]:

  • Injection
  • Tablets
  • Capsule
  • Others

Colony Stimulating Factor Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Aplastic Anemia
  • Bone Marrow Transplantation
  • Neutropenia
  • Neutropenia Associated With Chemotherapy
  • Neutropenia Associated With Radiation
  • Peripheral Progenitor Cell Transplantation

Colony Stimulating Factor Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Colony Stimulating Factor Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Colony Stimulating Factor Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies colony stimulating factor companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the colony stimulating factor companies profiled in this report include-

  • Intas Pharmaceuticals
  • Sanofi
  • Novartis
  • Teva Pharmaceutical Industries
  • Pfizer
  • GlaxoSmithKline
  • Biocon
  • Dr. Reddy's Laboratories
  • Amgen
  • Merck

Colony Stimulating Factor Market Insights

Lucintel forecasts that injection is expected to witness the highest growth over the forecast period.

Within this market, homecare is expected to witness the highest growth due to increasing adoption for homecare as a way to reduce healthcare costs and improve patient outcomes.

North America will remain the largest region over the forecast period due to increasing incidence of cancer among population and existence of robust healthcare system in the region.

Features of the Global Colony Stimulating Factor Market

Market Size Estimates: Colony stimulating factor market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Colony stimulating factor market size by various segments, such as by type, dosage, application, end use, and region in terms of value ($B).

Regional Analysis: Colony stimulating factor market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, dosages, applications, end uses, and regions for the colony stimulating factor market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the colony stimulating factor market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the colony stimulating factor market size?

Answer: The global colony stimulating factor market is expected to reach an estimated $13.7 billion by 2030.

Q2. What is the growth forecast for colony stimulating factor market?

Answer: The global colony stimulating factor market is expected to grow with a CAGR of 10.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the colony stimulating factor market?

Answer: The major drivers for this market are increasing prevalence of cancer and hematological diseases, rising investments in research and development for innovative treatments, and growing demand for advanced cancer therapies.

Q4. What are the major segments for colony stimulating factor market?

Answer: The future of the colony stimulating factor market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.

Q5. Who are the key colony stimulating factor market companies?

Answer: Some of the key colony stimulating factor companies are as follows:

  • Intas Pharmaceuticals
  • Sanofi
  • Novartis
  • Teva Pharmaceutical Industries
  • Pfizer
  • GlaxoSmithKline
  • Biocon
  • Dr. Reddy's Laboratories
  • Amgen
  • Merck

Q6. Which colony stimulating factor market segment will be the largest in future?

Answer: Lucintel forecasts that injection is expected to witness the highest growth over the forecast period.

Q7. In colony stimulating factor market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing incidence of cancer among population and existence of robust healthcare system in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the colony stimulating factor market by type (macrophage-colony-stimulating factor, multiple-colony-stimulating factor or interleukin 3, granulocyte-macrophage-colony-stimulating factor, and granulocyte-colony-stimulating factor), dosage (injection, tablets, capsule, and others), application (aplastic anemia, bone marrow transplantation, neutropenia, neutropenia associated with chemotherapy, neutropenia associated with radiation, and peripheral progenitor cell transplantation), end use (hospitals, specialty clinics, homecare, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Colony Stimulating Factor Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Colony Stimulating Factor Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Colony Stimulating Factor Market by Type
    • 3.3.1: Macrophage-Colony-Stimulating Factor
    • 3.3.2: Multiple-Colony-Stimulating Factor or Interleukin 3
    • 3.3.3: Granulocyte-Macrophage-Colony-Stimulating Factor
    • 3.3.4: Granulocyte-Colony-Stimulating Factor
  • 3.4: Global Colony Stimulating Factor Market by Dosage
    • 3.4.1: Injection
    • 3.4.2: Tablets
    • 3.4.3: Capsule
    • 3.4.4: Others
  • 3.5: Global Colony Stimulating Factor Market by Application
    • 3.5.1: Aplastic Anemia
    • 3.5.2: Bone Marrow Transplantation
    • 3.5.3: Neutropenia
    • 3.5.4: Neutropenia Associated with Chemotherapy
    • 3.5.5: Neutropenia Associated with Radiation
    • 3.5.6: Peripheral Progenitor Cell Transplantation
  • 3.6: Global Colony Stimulating Factor Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Specialty Clinics
    • 3.6.3: Homecare
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Colony Stimulating Factor Market by Region
  • 4.2: North American Colony Stimulating Factor Market
    • 4.2.1: North American Colony Stimulating Factor Market by Dosage: Injection, Tablets, Capsule, and Others
    • 4.2.2: North American Colony Stimulating Factor Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.3: European Colony Stimulating Factor Market
    • 4.3.1: European Colony Stimulating Factor Market by Dosage: Injection, Tablets, Capsule, and Others
    • 4.3.2: European Colony Stimulating Factor Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.4: APAC Colony Stimulating Factor Market
    • 4.4.1: APAC Colony Stimulating Factor Market by Dosage: Injection, Tablets, Capsule, and Others
    • 4.4.2: APAC Colony Stimulating Factor Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.5: ROW Colony Stimulating Factor Market
    • 4.5.1: ROW Colony Stimulating Factor Market by Dosage: Injection, Tablets, Capsule, and Others
    • 4.5.2: ROW Colony Stimulating Factor Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Colony Stimulating Factor Market by Type
    • 6.1.2: Growth Opportunities for the Global Colony Stimulating Factor Market by Dosage
    • 6.1.3: Growth Opportunities for the Global Colony Stimulating Factor Market by Application
    • 6.1.4: Growth Opportunities for the Global Colony Stimulating Factor Market by End Use
    • 6.1.5: Growth Opportunities for the Global Colony Stimulating Factor Market by Region
  • 6.2: Emerging Trends in the Global Colony Stimulating Factor Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Colony Stimulating Factor Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Colony Stimulating Factor Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Intas Pharmaceuticals
  • 7.2: Sanofi
  • 7.3: Novartis
  • 7.4: Teva Pharmaceutical Industries
  • 7.5: Pfizer
  • 7.6: GlaxoSmithKline
  • 7.7: Biocon
  • 7.8: Dr. Reddy's Laboratories
  • 7.9: Amgen
  • 7.10: Merck